SAN DIEGO and SUZHOU, China and SPRING HOUSE, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG) ...
Third Arc Bio is paying $5 million upfront to use Adagene’s tech in hopes of creating two new masked T-cell engagers. | Third ...
"Solid tumors are often difficult to treat because the immune system within the tumor gets switched off," said Michelle H. Nelson, PhD, Director of Immunobiology at Aptevo. "APVO451 is designed to ...
Exploratory Phase 2 analysis shows Verrica’s novel oncolytic peptide, VP-315, reprograms the tumor microenvironment, ...
HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing ...
Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies for cancer, today announced the publication of a peer-reviewed study titled "Antibody?Gamma/Delta T ...
Sino-American antibody company Adagene and Third Arc Bio today announced a licensing agreement under which Third Arc Bio will ...
Early immune activation marks the onset of rheumatoid arthritis, revealing potential for early intervention and improved ...
Detailed price information for Hcw Biologics Inc (HCWB-Q) from The Globe and Mail including charting and trades.
Aptevo Therapeutics (APVO) announced the first presentation of preclinical data for its new trispecific antibody, APVO451, at the Society for ...
Reported late-breaking Phase 2 data at SITC for vilastobart demonstrating a 40% ORR in heavily pretreated patients with MSS ...
One of the FDA’s potential approvals this month could break an existing monopoly in the treatment space for a rare growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback